ELIXIR and Toxicology: a community in development.
ELIXIR
FAIR
Toxicology
interoperability
Journal
F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320
Informations de publication
Date de publication:
2021
2021
Historique:
accepted:
28
09
2023
medline:
23
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Toxicology has been an active research field for many decades, with academic, industrial and government involvement. Modern omics and computational approaches are changing the field, from merely disease-specific observational models into target-specific predictive models. Traditionally, toxicology has strong links with other fields such as biology, chemistry, pharmacology and medicine. With the rise of synthetic and new engineered materials, alongside ongoing prioritisation needs in chemical risk assessment for existing chemicals, early predictive evaluations are becoming of utmost importance to both scientific and regulatory purposes. ELIXIR is an intergovernmental organisation that brings together life science resources from across Europe. To coordinate the linkage of various life science efforts around modern predictive toxicology, the establishment of a new ELIXIR Community is seen as instrumental. In the past few years, joint efforts, building on incidental overlap, have been piloted in the context of ELIXIR. For example, the EU-ToxRisk, diXa, HeCaToS, transQST, and the nanotoxicology community have worked with the ELIXIR TeSS, Bioschemas, and Compute Platforms and activities. In 2018, a core group of interested parties wrote a proposal, outlining a sketch of what this new ELIXIR Toxicology Community would look like. A recent workshop (held September 30th to October 1st, 2020) extended this into an ELIXIR Toxicology roadmap and a shortlist of limited investment-high gain collaborations to give body to this new community. This Whitepaper outlines the results of these efforts and defines our vision of the ELIXIR Toxicology Community and how it complements other ELIXIR activities.
Identifiants
pubmed: 37842337
doi: 10.12688/f1000research.74502.2
pmc: PMC10568213
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright: © 2023 Martens M et al.
Déclaration de conflit d'intérêts
No competing interests were disclosed.
Références
Nucleic Acids Res. 2019 Jan 8;47(D1):D1102-D1109
pubmed: 30371825
Toxicol Sci. 2018 Mar 1;162(1):264-275
pubmed: 29149350
Mol Inform. 2013 Jan;32(1):47-63
pubmed: 27481023
ALTEX. 2015;32(1):9-24
pubmed: 25372315
Environ Int. 2017 Feb;99:97-106
pubmed: 27939949
Environ Sci Technol. 2020 Mar 3;54(5):2575-2584
pubmed: 31968937
Nat Rev Drug Discov. 2017 Dec;16(12):811-812
pubmed: 29026211
Arch Toxicol. 2014 Dec;88(12):2323-32
pubmed: 25326818
Nat Genet. 2012 Jan 27;44(2):121-6
pubmed: 22281772
Chem Res Toxicol. 2016 Aug 15;29(8):1225-51
pubmed: 27367298
Nucleic Acids Res. 2015 Jan;43(Database issue):D921-7
pubmed: 25313160
Genome Biol. 2019 Aug 12;20(1):164
pubmed: 31405382
Int J Mol Sci. 2014 Nov 14;15(11):21136-54
pubmed: 25405742
Genes Nutr. 2018 Apr 30;13:12
pubmed: 29736190
Beilstein J Nanotechnol. 2015 Jul 27;6:1609-34
pubmed: 26425413
Regul Toxicol Pharmacol. 2013 Oct;67(1):1-12
pubmed: 23764304
Science. 2020 Jan 24;367(6476):388-392
pubmed: 31974244
Environ Sci Technol. 2014 Nov 4;48(21):12760-7
pubmed: 25343693
Nucleic Acids Res. 2021 Jan 8;49(D1):D1502-D1506
pubmed: 33211879
Biochimie. 2018 Sep;152:155-158
pubmed: 29960033
J Cheminform. 2021 Jul 7;13(1):50
pubmed: 34229711
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
F1000Res. 2018 Jun 14;7:
pubmed: 31543945
J Cheminform. 2011 May 16;3:18
pubmed: 21575202
Nucleic Acids Res. 2019 Jan 8;47(D1):D711-D715
pubmed: 30357387
Bioinformatics. 2013 May 15;29(10):1325-32
pubmed: 23479348
Chem Res Toxicol. 2014 Mar 17;27(3):314-29
pubmed: 24446777
J Cheminform. 2017 Nov 28;9(1):61
pubmed: 29185060
Sci Data. 2016 Mar 15;3:160018
pubmed: 26978244
Nat Commun. 2017 Jul 03;8:15932
pubmed: 28671182
Nanomaterials (Basel). 2020 Oct 20;10(10):
pubmed: 33092028
ALTEX. 2016;33(2):95-109
pubmed: 26863090
J Biomed Semantics. 2015 Mar 21;6:10
pubmed: 25815161
Curr Opin Pharmacol. 2014 Dec;19:105-11
pubmed: 25244397
Int J Hyg Environ Health. 2017 Mar;220(2 Pt A):94-97
pubmed: 28284775
J Chem Inf Model. 2022 Oct 24;62(20):4888-4905
pubmed: 36215146
F1000Res. 2017 Sep 6;6:
pubmed: 29043062
Nucleic Acids Res. 2019 Jan 8;47(D1):D1172-D1178
pubmed: 30407529
Mol Inform. 2010 Jul 12;29(6-7):476-88
pubmed: 27463326
Environ Sci Technol. 2019 Jan 15;53(2):719-732
pubmed: 30516957
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1847-50
pubmed: 16103423
Trends Biotechnol. 2012 May;30(5):241-2
pubmed: 22417641
Nat Biotechnol. 2019 Apr;37(4):358-367
pubmed: 30940948
Environ Sci Eur. 2018;30(1):5
pubmed: 29568720
Bioinformatics. 2015 May 1;31(9):1505-7
pubmed: 25505093
Arch Toxicol. 2017 Nov;91(11):3477-3505
pubmed: 29051992
Bioinformatics. 2020 May 1;36(10):3290-3291
pubmed: 32044952
Arch Toxicol. 2016 May;90(5):1021-4
pubmed: 27017488
Drug Discov Today. 2012 Nov;17(21-22):1188-98
pubmed: 22683805
Science. 2020 Jan 24;367(6476):392-396
pubmed: 31974245
J Cheminform. 2014 May 14;6:25
pubmed: 24910716
Int J Mol Sci. 2020 Apr 23;21(8):
pubmed: 32340264
Chem Res Toxicol. 2020 Jan 21;33(1):7-9
pubmed: 31909603
Interdiscip Toxicol. 2009 Jun;2(2):42-4
pubmed: 21217844
Pharmaceuticals (Basel). 2021 Mar 08;14(3):
pubmed: 33800393
Pharmacogenomics. 2006 Oct;7(7):1025-44
pubmed: 17054413
NanoImpact. 2018 Jan;9:85-101
pubmed: 30246165